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Background—Evidence on economically efficient strategies to lower blood pressure (BP) from low- and middle-income
countries remains scarce. The Control of Blood Pressure and Risk Attenuation (COBRA) trial randomized 1341
hypertensive subjects in 12 randomly selected communities in Karachi, Pakistan, to 3 intervention programs: (1)
combined home health education (HHE) plus trained general practitioner (GP); (2) HHE only; and (3) trained GP only.
The comparator was no intervention (or usual care). The reduction in BP was most pronounced in the combined group.
The present study examined the cost-effectiveness of these strategies.
Methods and Results—Total costs were assessed at baseline and 2 years to estimate incremental cost-effectiveness ratios
based on (1) intervention cost; (2) cost of physician consultation, medications, diagnostics, changes in lifestyle, and
productivity loss; and (3) change in systolic BP. Precision of the incremental cost-effectiveness ratio estimates was
assessed by 1000 bootstrapping replications. Bayesian probabilistic sensitivity analysis was also performed. The annual
costs per participant associated with the combined HHE plus trained GP, HHE alone, and trained GP alone were $3.99,
$3.34, and $0.65, respectively. HHE plus trained GP was the most cost-effective intervention, with an incremental
cost-effectiveness ratio of $23 (95% confidence interval, 6–99) per mm Hg reduction in systolic BP compared with
usual care, and remained so in 97.7% of 1000 bootstrapped replications.
Conclusions—The combined intervention of HHE plus trained GP is potentially affordable and more cost-effective for BP
control than usual care or either strategy alone in some communities in Pakistan, and possibly other countries in
Indochina with similar healthcare infrastructure.
Clinical Trial Registration—http://www.clinicaltrials.gov. Unique identifier: NCT00327574.
(Circulation. 2011;124:1615-1625.)
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Cardiovascular diseases (CVD) have become the leadingcause of death worldwide, and will particularly affect
younger adults in developing countries, with major adverse
consequences for national economies. Hypertension confers
the highest attributable risk of death from CVD.1
Clinical Perspective on p 1625
The burden of hypertension has reached epidemic proportions
in Indo-Asian countries, affecting a third of adults in Pakistan.2
However, public spending on health, especially chronic disease
prevention, remains abysmally low in the face of competing
priorities.3 Private providers are the frontline caregivers, and are
visited frequently. However, serious deficiencies have been
identified in their knowledge and practices with regard to the
management of hypertension.4 Furthermore, there are no na-
tional strategies for the control of hypertension or similar efforts
to enhance care by private providers. As highlighted in the recent
Institute of Medicine Report on Cardiovascular Diseases in low-
and middle-income countries, advocating both public and pri-
vate sector changes requires locally obtained relevant empirical
evidence on sustainable, cost-effective, and affordable
population-based strategies for the prevention and control of
hypertension, which is scarce.5 Recently, we reported the results
of a large cluster-randomized factorial design trial on
community-based strategies of home health education (HHE)
and training of general practitioners (GPs) to control high blood
pressure (BP).6 We found that BP declined in all groups, but the
reduction was most pronounced in those randomized to the
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combination of both strategies compared with either intervention
or no intervention.
However, neither the cost nor the cost-effectiveness of
the interventions was reported.5 This information is essen-
tial for policymakers and health planners because clini-
cally effective interventions may not necessarily represent
value for money compared with the alternatives studied in
this resource-poor country.7
We therefore conducted these analyses to determine (1) the
cost of the interventions from the affordability perspective of
the policymakers and (2) the incremental cost-effectiveness
of the total healthcare costs related to the interventions
compared with usual care in terms of per mm Hg reduction in
BP from the societal perspective. An intervention cost from
the policymakers’ perspective within 10% of the existing
national healthcare (government spending) budget was con-
sidered affordable.8 The lowest incremental cost-
effectiveness ratio (ICER) (most BP reduction at least total
healthcare cost relative to usual care) that was also signifi-
cantly different compared with usual care (ie, bootstrapped
95% confidence intervals [CIs] also consistent with the mean
value in direction and magnitude) was considered most
cost-effective. We hypothesized that the combined HHE plus
GP intervention would be more cost-effective than single
interventions or usual care.
Methods
The Control of Blood Pressure and Risk Attenuation (COBRA) trial
was a cluster randomized, controlled trial with a 22 factorial design
to determine the impact of family-based HHE and/or special training
of GPs on the BP levels of adults aged 40 years with hypertension
(http://www.clinicaltrials.gov; unique identifier NCT00327574).6
The sampling frame and study design details have been described
previously.6 Briefly, multistage cluster sampling techniques were
used to randomly select 12 communities (with 250 households
each) from middle- to low-income areas in Karachi. Individuals aged
40 years residing in the 12 clusters with known hypertension or
with consistently elevated BP on 2 separate visits (mean of last 2 of
3 measurements of systolic pressure 140 mm Hg or mean diastolic
pressure 90 mm Hg) were eligible for inclusion in the study. The
12 clusters were then randomly assigned to 4 groups of 3 clusters
each: HHE, trained GP, HHE plus trained GP, and no intervention
(Table 1).
Home Health Education
Six community health workers (1 for each cluster) trained over 6
weeks provided advice at 3-month intervals on the importance of
engaging in moderate physical activity; maintaining normal body
weight; reducing salt intake; maintaining an adequate intake of
potassium; consuming a diet rich in fruit, vegetables, and low-fat
dairy products and low in saturated and total fat (including sample
recipes for culturally acceptable and economically feasible food
products); and smoking cessation.9 This intervention was modeled
on the existing Lady Health Workers Program in Pakistan. The
details of training have been published previously.6
Table 1. Comparison of Baseline Participant Characteristics by Interventions
Characteristic
HHE and
Trained GP HHE Only
Trained
GP Only
No
Intervention
Cluster characteristics
Clusters, n 3 3 3 3
Households, n 656 673 657 664
Mean residents per household, n (SD) 6.5 (3.0) 6.7 (3.0) 6.6 (3.0) 6.4 (3.1)
No. of GPs 61 61 58 69
Patient characteristics
Households, n 278 283 281 275
Hypertension, n 332 348 335 326
Age, mean (SD), y 54.0 (11.5) 52.7 (11.4) 55.3 (11.5) 53.3 (11.5)
Male, n (%) 112 (33.7) 133 (38.2) 138 (41.2) 118 (36.2)
Education level, n (%)
Illiterate 131 (39.5) 110 (32.8) 151 (43.4) 162 (49.7)
Primary or higher 201 (60.5) 197 (56.6) 225 (67.1) 164 (50.3)
Current smoker, n (%) 23 (37.7) 36 (48.6) 46 (54.8) 37 (56.9)
Physical activity MET score 840, n (%)* 96 (28.9) 116 (33.3) 96 (28.7) 148 (45.4)
Low socioeconomic status, n (%)† 232 (69.9) 246 (70.7) 188 (56.1) 266 (81.6)
Sought ambulatory care in last 2 wk, n (%) 109 (32.8) 113 (32.5) 94 (28.1) 105 (32.2)
Total No. of GP visits in last 2 wk 278 279 201 287
Employment status, n (%)
Currently employed 99 (29.8) 107 (30.7) 109 (32.5) 92 (28.2)
Jobless 9 (2.7) 13 (3.9) 13 (3.9) 12 (3.7)
Housewives 190 (57.2) 199 (57.2) 178 (53.1) 191 (58.6)
Retired 34 (10.2) 29 (8.3) 35 (10.4) 31 (9.5)
HHE indicates home health education; GP, general practitioner; and MET, metabolic equivalent.
*Calculated as total MET min/wkwalk (MET mind)moderate (MET mind)vigorous (MET mind).
†Monthly household income $70 as reported by the Federal Bureau of Statistics.
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GP Training
All GPs in the 6 study areas assigned to this intervention were invited
for training, with the realistic aim to train at least two thirds of all
GPs from each area. The annual training was a 1-day session focused
on standard treatment for the management of hypertension, based on
the Seventh Report of the Joint National Committee and the Fourth
Working Party of the British Hypertension Society guidelines
modified for the Indo-Asian population.10,11
All study participants aged 40 years with hypertension were
advised to consult a local GP. Those in the clusters randomized to the
trained GP arm were given a list of trained GPs within their cluster.
However, GP selection remained the choice of the participants.
There was no provision for supplying medications or reimbursing
fees for healthcare services in the study. The participation by
subjects and GPs was voluntary.
Screening and Recruitment
All households in each cluster were visited, and informed consent
was obtained for screening from all adults aged40 years, who then
underwent measurement of BP 3 times with a calibrated automated
device (Omron HEM-737 IntelliSense; Omron Healthcare Inc, Ver-
non Hills, IL) in the sitting position after 5 minutes of rest. Those
with an elevated BP and not on antihypertensive medication were
visited again for remeasurement of BP 1 to 4 weeks after the initial
visit. If mean BP remained elevated, these individuals were invited
to participate. In addition, those with known hypertension were also
invited to participate, irrespective of measured BP.
Hypertensive adults were evaluated by trained field staff, masked
to randomization status, at baseline and at 4-month intervals when 3
consecutive BP readings were taken. Information on diet (food
frequency and expenditure on fruits and vegetables), physical activ-
ity (international physical activity questionnaire), current antihyper-
tensive medications, frequency of visits to health providers in the last
2 weeks, expenditure on healthcare costs (provider fee, medications,
and laboratory costs), and any hospitalizations was collected. Infor-
mation on days of work lost because of illness during this period was
recorded. BP was measured as described above. The planned median
duration of follow-up was 2 years.
Costs
We estimated the cumulative intervention costs over 2 years. These
costs included personnel, equipment, and training material and
supplies for development of curricula, transport, and other opera-
tional expenses over 2 years (Table 2). Personnel costs for the
interventions included salaries and fringe benefits of faculty, a
nutritionist (for HHE), and community health workers (7 full-time
workers for HHE and 6 part-time field workers for the trained GP
group). To account for office rent and maintenance, an administra-
tive cost of 30% was applied to intervention costs. Because 1 of the
goals was to assess affordability from the policymakers’ perspective
and implications for public funds, only the intervention cost was
used for this purpose.
The cost-effectiveness analyses were performed from a societal
perspective and therefore needed to account for total healthcare
costs. These costs included the cost of intervention, patient costs for
healthcare and related lifestyle (diet), and productivity losses. The
patient costs for healthcare included payments made by patients to
the healthcare provider, the cost of purchasing medications, and
expenditures for diagnostics. Patient data on costs were collected
from participants at baseline and final visit by questionnaire. The
questionnaire was administered in the homes of respondents by
trained interviewers. Participants (from all 4 groups) were asked to
provide detailed information on any medical consultations, medica-
tions purchased, medical tests conducted, and periods of hospital-
ization during the previous 2 weeks. These cost data were annualized
to determine the direct annual healthcare cost for all 4 groups at
baseline and final follow-up visit (Table 3). This rationale was
consistent with our analysis of the primary effectiveness outcome of
change in BP, as reported previously.6 For the cost-effectiveness
analysis, the difference in annualized cost from baseline to follow-up
for each group was projected over 2 years, with adjustment for
inflation.
The cost of fruit and vegetables was also included in the societal
aspect of lifestyle modification. Information on fruits and vegetables
and meat purchased by the household during the previous 2 weeks
was collected, and because interventions were delivered at the
community level, the denominator for per-patient calculation was all
subjects aged 5 years.
In accordance with the recommendation of Gold et al12 in regard
to the importance of accounting for the patients’ and caregivers’
time, values for productivity losses were imputed for the opportunity
costs to participants and caregivers, irrespective of whether or not
they were engaged in paid employment. We used the average market
wage rate for men and women in urban Sindh (Government of
Pakistan, 2009) as the value of time lost.12,13
Productivity losses resulting from illness and treatment were
imputed for participants and projected over 2 years.
Because BP screening by community health workers was common
to all 4 randomized groups, the cost of screening was not considered
in the comparative analysis. However, it was included in estimating
the impact of upscaling strategies on the national health budget, and
for this it was assumed that the BP monitors would have a useful life
of 5 years with no resale value after that.
All costs are reported in US dollars at the 2007 rate. To control for
inflation, all costs were inflated to prices in 2007, with the use of the
gross domestic product deflator of 7.7% for Pakistan.14 The mean
exchange rate for the year was used to convert costs from Pakistan
rupees into US dollars. To adjust for time preference, all costs and
effects were discounted; in accordance with the International Society
for Pharmacoeconomics and Outcomes Research guidelines, an
annual discount rate of 5% over 2 years was used.15,16
Effectiveness
The primary outcome measure for the study was the change in
systolic BP from baseline to the last follow-up visit. The secondary
outcome measure was the proportion of participants with controlled
BP (140 mm Hg for systolic BP and 90 mm Hg for diastolic BP)
at the last follow-up visit.
Statistical Analysis
We compared the costs of each randomized intervention to the
no-intervention group on an intention-to-treat principle.
Table 2. Annual Intervention Cost per Participant
Characteristic
HHE and
Trained GP
HHE
Only
Trained
GP Only
No
Intervention
Personnel* 2.77 2.46 0.31 . . .
Equipment† 0.14 0.14 . . . . . .
Training supplies‡ 0.22 0.14 0.08 . . .
Transport 0.38 0.37 0.01 . . .
Indirect cost§ 0.47 0.23 0.24 . . .
Total 3.99 3.34 0.65 . . .
HHE indicates home health education; GP, general practitioner. All expenses
are expressed in US dollars, valued at exchange rate in July 2007 (1 US
dollar61 Pakistan rupees).
*Three assistant professors at $1336 per person per month; 1 nutrition
consultant at 5% effort for $70 per month for 24 mo; 1 nutrition trainer at 50%
effort for $185 per month for 24 mo; 7 community health workers at $123 per
person per month over 2 y; 8 workers for part-time work at $48.4 per person
for 1 month; and 2 part-time chaperones at $34.60 per month.
†Three computers for total of $2594, 1 digital video disc player for $112,
and compact discs for $10 for all 3 interventions.
‡Printing costs of training manuals and charts of $750 in HHE group and
$1190 in trained GP group and costs of office stationary and photocopies of
$1743 in HHE group and $333 in trained GP group.
§Office rent at $4358 per month; indirect cost is 30% of all direct costs.
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ICERs were computed to compare the additional costs and effects
of each intervention with the other.12 Uncertainty in the point
estimate of the ICERs was investigated with the use of a nonpara-
metric bootstrap with 1000 replications varying the BP effects while
costs remained the same.8 The bootstrap was used to estimate 95%
CIs around differences in ICERs between randomized groups and to
produce scatterplots for the interventions on a cost-effectiveness
plane (Figure).17,18
Cost per CVD Disability-Adjusted
Life-Year Averted
To facilitate comparison with other programs for competing priori-
ties, the most cost-effective of the alternatives considered was
expressed in terms of the cost per disability-adjusted life-year
(DALY) averted. The DALY is a generic measure of the burden of
disease that combines healthy life-years lost because of premature
mortality with those lost as a result of disability.19 The metric thus
enables assessment of burden of disease and is helpful for policy-
makers for resource allocation during health planning.
To assess the impact on the national health budget, the cost per
participant of intervention was translated into per capita cost for the
population of Pakistan from the policymakers’ perspective. In
addition, the per capita cost per CVD DALY averted analysis was
performed from both the policymakers’ and the societal perspectives.
Because the relationship between the fall in BP and the impact on
CVD events is linear and well defined, a reduction of 5 mm Hg in BP
was assumed to lead to 20% reduction in CVD DALYs.20–22 The
cost of 1 CVD DALY averted was computed for an annual burden of
3 176 000 DALYs from CVD for Pakistan, as observed in the Global
Burden of Disease Study 2004.23
Sensitivity Analysis
We undertook a number of sensitivity analyses to assess the impact
of uncertainty on the estimates of cost-effectiveness. These included
different discount rates of costs and values of systolic BP effective-
ness, exclusion of productivity losses, and additional cost inputs,
including lifestyle factors such as smoking, expense related to meat
consumption, productivity loss of caregiver’s time while chaperon-
ing GP visits, and exclusion of lifestyle-related costs (ie, fruit and
vegetables). Probabilistic sensitivity analysis with the use of Bayes-
ian principles was conducted to assess simultaneous changes in all
patient level variables involved in the costs and main effects. Monte
Carlo simulation was performed to determine the mean costs, effects
on BP, and ICERs among the treatment groups. We also computed
ICERs for the primary outcome incrementally to compare the least
costly with the next more costly intervention.24
From the societal perspective, the incremental cost per CVD
DALY averted was also computed on the basis of incremental cost
estimates from the simulated models. In addition, CVD DALYs
averted were computed for declining persistence of effect despite
Table 3. Patient Level Costs for 2 Years in US Dollars
Expenditures
HHE and
Trained GP
(n332)
HHE Only
(n348)
Trained
GP Only
(n335)
No
Intervention
(n326) P *
GP consultations
At baseline 61.9 44.3 33.3 45.6 0.182
At final visit 16.3 12.0 19.4 17.7 0.202
Medication
At baseline 58.6 46.4 70.2 67.1 0.234
At final visit 162.2 107.4 133.7 117.5 0.021
Laboratory
At baseline 13.2 15.3 15.4 6.1 0.862
At final visit 40.7 9.0 37.1 45.6 0.071
Total expenses for healthcare
At baseline 133.7 106.0 118.8 118.8 0.303
At final visit 219.2 128.3 190.2 180.9 0.021
Fruit and vegetables
At baseline 105.6 101.0 114.3 94.9 0.161
At final visit 81.8 82.2 98.0 86.7 0.132
Total patient costs for health
including main analysis†
At baseline 241.2 196.3 229.1 206.2 0.295
At final visit 306.0 206.0 283.4 258.8 0.020
Meat consumption
At baseline 9.1 8.8 10.1 8.5 0.632
At final visit 6.7 7.8 10.0 8.2 0.001
Smoking
At baseline 0.5 1.0 1.0 1.0 0.201
At final visit 0.6 0.9 0.8 0.8 0.543
HHE indicates home health education; GP, general practitioner. All expenses are expressed in US dollars, valued at
exchange rate in July 2007 (1 US dollar61 Pakistan rupees).
*P values are calculated on the basis of raw data.
†Total patient costs for health including main analysis composed of GP consultation, medication, laboratory, and fruit
and vegetable expenses.
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continued intervention assuming a reduction of 1% annually, thus
ranging from 20% to 10% or a 50% reduction in benefit.
Finally, we also performed an additional sensitivity analysis to
estimate the cost-effectiveness of the interventions in a high-income
country like the United States, assuming similar effectiveness on BP
with application of US cost estimates. The latter was done by (1)
converting all costs in Pakistan rupees to the US international dollar
equivalent corresponding to purchasing power parity for the year
2007 (1 US dollar22.7 Pakistan rupees) and (2) specific replace-
ment of itemized costs in Pakistan with US estimates related to GP
consultation fee, personnel and health workers’ salaries, medica-
tions, and diagnostics, which take into account the higher healthcare
prices in the United States.25 The cost of 1 CVD DALY averted was
based on the ICER for US cost data and computed for an annual
burden of 5 853 000 DALYs from CVD, as observed in the Global
Burden of Disease Study 2004.
All authors had full access to the data and take responsibility for
the integrity of the data and the accuracy of the data analysis.
Results
Overall, 1341 study participants were randomized: 332 to HHE
plus trained GP, 348 to HHE only, 335 to trained GP only, and
326 to no intervention. The baseline characteristics of hyperten-
sive adults in the randomized groups are shown in Table 1. A
total of 1044 subjects (78%) completed 2 years of follow-up.
Intervention and Resource Utilization Costs
The annual intervention costs per participant (ie, from the
perspective of the policymaker) varied substantially for
the intervention groups, with the most expensive being the
joint intervention group, which was 4 times higher than
the GP intervention only group (Table 2).
The expenditures per participant for direct healthcare,
including physician consultation, medications, and diagnos-
tics at baseline and follow-up are shown in Table 3. The use
and associated cost of antihypertensive medications increased
from baseline to follow-up in all groups; this increase was
more pronounced in the groups with trained GPs (Table 4).
The decrease in expenditure on fruit and vegetables was most
marked in the combined HHE plus trained GP group, prob-
ably reflecting a shift to low-cost seasonal produce, as
advised. However, despite emphasis during GP training that
thiazide diuretics be the first-line agent for most hypertensive
patients, their use remained low (3% in all groups).
Effectiveness
As reported previously, systolic BP declined in all 4 groups. The
decline in systolic BP (adjusted for age, sex, and baseline BP)
Figure. Incremental cost-effectiveness plane at 5% discounting. Bootstrap replications show the effect differences in change in blood
pressure between randomized treatment programs vs usual care on the x axis. An effect of 0 means greater reduction in blood pres-
sure in the treatment group. The proportions on the graphs indicate the percentage of values of the1000 replications for which effect
difference was 0. The y axis shows the cost difference between intervention and usual care. Positive values suggest that the interven-
tion is more expensive than usual care and vice versa. Relative to the control group (usual care) at the origin, the incremental costs are
divided across the horizontal axis of the plane (higher positive, lower negative) and the incremental effect by the vertical axis (higher to
the right, lower to the left). Thus, each quadrant has a different implication for the choice of intervention. Interventions with incremental
cost-effectiveness ratios falling in the southeast quadrant would be more effective and less costly and therefore always cost-effective
relative to the comparator. Interventions with incremental cost-effectiveness ratios in the northwest quadrant would be less effective
and more costly and not cost-effective. An intervention with incremental cost-effectiveness ratios falling in the northeast quadrant would
be more effective but also more costly; consequently, a trade-off between costs and effects would need to be considered, because this
would represent a situation in which interventions may be cost-effective compared with usual care, depending on the value at which
the incremental cost-effectiveness ratio is considered good value for investment. HHE indicates home health education; GP, trained
general practitioner group.
Table 4. Use of Antihypertensive Medications by Intervention*
HHE and Trained GP
(n332)
HHE Only
(n348)
Trained GP Only
(n335)
No Intervention
(n326)
Baseline, % (95% CI) 35.2 (30.3–40.5) 39.7 (34.7–44.9) 35.5 (30.6–40.8) 40.5 (35.3–45.9)
Follow-up, % (95% CI) 49.7 (44.4–55) 46 (40.8–51.2) 46.3 (41–51.6) 48.8 (43.4–54.2)
% Change (95% CI) 14.5 (11.1–18.6) 6.3 (4.2–9.4) 10.8 (7.9–14.5) 8.3 (5.8–11.8)
HHE indicates home health education; GP, general practitioner; and CI, confidence interval.
*The analysis was performed at the patient level, and therefore use of 1 antihypertensive medication by a
patient was counted as 1.
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was significantly more pronounced in the HHE plus trained GP
care group (11 mm Hg; P0.001) compared with the other
groups (6 mm Hg in each). We also detected a significant
interaction in the proportion of patients with controlled BP
(P0.001) between the main effects of GP training and HHE.
Thus, a substantially greater proportion of patients (56.9%)
achieved controlled BP in the HHE and trained GP group than in
the other groups (trained GP only, 29.0%; HHE only, 23.0%; no
intervention, 27.3%; P0.003 for difference among groups).
The mean per capita expenditure by respondents on all health-
care over 2 years is shown in Table 5. Although the direct costs
for HHE plus trained GP were highest at $189, the reported
productivity loss was greatest for the trained GP group. The
expenditure on fruits and vegetables was also highest in the
latter, which was partly responsible for the overall highest costs
at $538 for the trained GP group.
Incremental Cost-Effectiveness Ratios
From a societal perspective, the combined intervention of
HHE plus trained GP yielded a bootstrapped ICER of $23
(95% CI, 6–99) per mm Hg reduction in systolic BP com-
pared with no intervention (usual care) (Table 5). When
discounted at 5%, the combined intervention of HHE plus
trained GP yielded an ICER of $23 (95% CI, 7–101)
per mm Hg reduction in systolic BP compared with no
intervention (usual care). Whether discounted or undis-
counted, the ICERs associated with the single interventions
were less cost-effective (Table 5) because their CIs were wide
in magnitude and direction, ranging from dominant to posi-
tive ICERs. Scatterplots of the bootstrapped ICERs illustrate
these results (Figure).
Per Capita Cost of Intervention and Cost per
CVD DALY Averted for Pakistan
On the basis of a hypertension prevalence of 18% in
Pakistani adults aged 15 years2 (and 60% of the population
is in this age range), the estimated cost of the annual
combined intervention of HHE and GP training of $3.99 per
participant translates into an annual per capita cost of $0.43
for the Pakistani population of 170 000 000.26 From the
policymakers’ perspective, the HHE plus GP training inter-
vention was estimated to cost $115 per CVD DALY averted.
From a societal perspective, the incremental cost of the
combined intervention versus usual care was $1226 per CVD
DALY averted. Moreover, the additional cost of screening for
BP would be $0.06, and thus the cumulative per capita cost
incurred to scale up the combined HHE plus GP intervention
and BP screening would be US $0.49.
Sensitivity Analyses
Sensitivity analysis of the outcome parameter by varying change
in systolic BP from the trial during computation of 95% limits of
ICER confirmed the cost-effectiveness of HHE plus trained GP
over the other interventions. Furthermore, exploration of the
implications of simultaneous alteration in costs and effects,
application of discount rates of 3% and 10% (as recommended
by the International Society for Pharmacoeconomics and Out-
comes Research),12 additional and reduced costs, as well as
Table 5. Cost and Cost-Effectiveness by Intervention Groups Over 2 Years in US Dollars
Characteristic
HHE and
Trained GP
(n332)
HHE Only
(n348)
Trained
GP Only
(n335)
No
Intervention
(n326) P *
Patient level costs†
GP consultations 45.0 32.4 29.5 36.0 0.902
Medication 116.0 81.3 108.6 98.7 0.862
Laboratory 28.2 13.6 27.7 26.4 0.303
Total expenses for healthcare 189.1 127.3 165.8 161.1 0.161
Fruit and vegetables 103.7 101.2 117.0 99.8 0.295
Total patient costs for healthcare‡ 296.5 219.8 278.1 252.1 0.129
Productivity loss in US $5.72 195.4 166.7 258.4 205.3 0.177
Intervention cost 8.0 6.7 1.3 . . .
Mean SBP effect (95% CI) 10.8 (8.9–12.8) 5.6 (3.7–7.4) 5.6 (3.7–7.5) 5.8 (3.9–7.7)
Total cost§ 499.9 393.2 537.8 457.4
ICER 23 (6–99) Dominated (dominated to 714) 201 (dominated to 790) . . .
5% Discounting
Mean SBP effect 9.8 5.1 5.1 5.3
Total cost§ 464.9 365.7 500.2 425.4
ICER 23 (7–101) Dominated (dominated to 730) 206 (dominated to 807) . . .
HHE indicates home health education; GP, general practitioner; CI, confidence interval; SBP, systolic blood pressure; and ICER, incremental cost-effectiveness ratio.
All expenses are expressed in US dollars, valued at exchange rate in July 2007 (1 US dollar61 Pakistan rupees).
*P values are calculated on the basis of raw data.
†Patient level costs are computed on the basis of average of inflated baseline and final visit.
‡Total patient costs for healthcare including GP consultation, medication, laboratory, and fruit and vegetable expenses.
§Total cost includes total patient cost for healthcare, productivity loss, and intervention cost.
ICER calculated on the basis of boot strapping.
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Table 6. Sensitivity Analyses
Characteristic
HHE and
Trained GP
(n332)
HHE Only
(n348)
Trained
GP Only
(n335)
No
Intervention
(n326)
Bayesian probabilistic sensitivity analysis
Mean SBP effect, mm Hg (95% CI) 10.8 (8.9–12.8) 5.6 (3.7–7.4) 5.6 (3.7–7.5) 5.8 (3.9–7.7)
Total cost* 499.9 393.2 537.8 457.4
ICER† 22 (7–104) Dominated (dominated to 416) 85 (dominated to 642) . . .
Excluding productivity losses
Mean SBP effect, mm Hg (95% CI) 10.8 (8.9–12.8) 5.6 (3.7–7.4) 5.6 (3.7–7.5) 5.8 (3.9–7.7)
Total cost‡ 304.5 226.5 279.4 252.1
ICER† 28 (8–123) Dominated (dominated to 248) 68 (dominated to 267) . . .
3% Discounting
Mean SBP effect, mm Hg 10.2 5.3 5.3 5.5
Total cost* 477.4 375.5 513.6 436.8
ICER† 23 (7–100) Dominated (dominated to 726) 204 (dominated to 802) . . .
10% Discounting
Mean SBP effect, mm Hg 9.0 4.6 4.6 4.8
Total cost* 434.9 342.1 467.9 398.0
ICER† 24 (7–104) Dominated (dominated to 749) 211 (dominated to 828) . . .
Assuming increased use of thiazides by patients
receiving care by trained GPs§
Mean SBP effect, mm Hg 10.8 5.6 5.6 5.8
Total cost§ 459.3 393.2 499.8 457.4
ICER† 10 (3–46) Dominated (dominated to 714) 155 (dominated to 611) . . .
Additional patient cost inputs
Meat consumption 8.8 9.2 11.0 9.1
Smoking 0.6 1.0 1.0 1.0
Mean SBP effect, mm Hg 10.8 5.6 5.6 5.8
Total cost 313.9 236.7 291.4 262.2
ICER† 27 (7–116) Dominated (dominated to 227) 92 (dominated to 361) . . .
Additional patient cost and productivity losses
Productivity loss for caregiver at US $5.72 52.9 44.5 69.3 60.2
Mean SBP effect, mm Hg 10.8 5.6 5.6 5.8
Total cost# 562.1 447.9 619.1 527.8
ICER† 17 (5–75) Dominated (dominated to 883) 248 (dominated to 973) . . .
Excluding cost of fruit and vegetables
Mean SBP effect, mm Hg 10.8 5.6 5.6 5.8
Total cost** 392.5 300.7 425.5 366.5
ICER† 13 (4–55) Dominated (dominated to 755) 143 (dominated to 558) . . .
US costs based on purchasing power parity
Mean SBP effect, mm Hg 10.8 5.6 5.6 5.8
Total cost†† 1346.2 1058.9 1448.4 1231.9
ICER† 62 (17–266) Dominated (dominated to 1923) 542 (dominated to 2127) . . .
(Continued)
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application of US cost estimates all revealed the cost-
effectiveness of combined HHE plus trained GP over trained
GP, HHE, or no intervention (Table 6). The cost per DALY
averted for Pakistan increased from $115 to $230 at the policy-
maker level and from $1226 to $2451 at the societal level with
modeling of declining persistence of cardiovascular benefit from
20% to 10%, respectively (Table 7).
The approach of comparing the least to the next more
costly intervention (ie, HHE compared with the combined
intervention of HHE plus trained GP) yielded an ICER of
$77.8 (95% CI, 19.9–275.8) per mm Hg reduction in BP,
which translates into $3600 per CVD DALY saved.
From a societal perspective for the United States, on the basis
of the prevalence of hypertension of 24% as observed in the
Third National Health and Nutrition Examination Survey in
adults aged 18 years27 (and 80% of the population is in this
age range), the estimated cost per DALY was I$5770 for the
international purchasing power parity cost replacement and
$40 466 per DALY averted for itemized replacement of costs.
Discussion
We found that the combined intervention of HHE by lay
health workers and management by trained GPs was more
cost-effective for lowering BP than the use of trained GP,
HHE, or no intervention in the communities in Karachi. The
combined HHE plus GP group was the most cost-effective
compared with other interventions, was associated with the
bootstrapped ICER of $23 (95% CI, 6–99) per mm Hg
reduction in systolic BP compared with usual care, and
remained so in 97.7% of 1000 bootstrapped replications.
According to the US Panel on Cost-Effectiveness in Health
and Medicine, there are no absolute standards for accepting
an intervention as cost-effective or not cost-effective on the
basis of cost-effectiveness ratios.28 However, the ICER offers
a comparative estimate relative to the next best alternative
and is therefore more informative for decision making.
Our analyses indicate that from the policymakers’ perspec-
tive, the combined HHE and trained GP intervention was the
most costly (annual cost per participant of $3.99) of the 3
Table 6. Continued
Characteristic
HHE and
Trained GP
(n332)
HHE Only
(n348)
Trained
GP Only
(n335)
No
Intervention
(n326)
US costs based on individually modified estimates
Mean SBP effect, mm Hg 10.8 5.6 5.6 5.8
Total cost†† 11744.3 9140.0 12139.2 10943.2
ICER† 416 (113–1860) Dominated (dominated to 19 722) 3011 (dominated to 11 809) . . .
HHE indicates home health education; GP, general practitioner; SBP, systolic blood pressure; CI, confidence interval; and ICER, incremental cost-effectiveness ratio.
All expenses are expressed in US dollars, valued at exchange rate in July 2007 (1 US dollar61 Pakistan rupees).
*Total cost includes total patient costs for health, productivity loss, and intervention cost as in the main model.
†ICER calculated on the basis of boot strapping.
‡Costs include total patient costs for health and intervention costs as in the main model.
§Cost of medications reduced by a conservative estimate of 50% in 70% of patients on antihypertensive medications in HHE plus GP and trained GP only groups,
assuming they were on generic thiazide costing 50% of their current medication.
Additional patient cost inputs include cost of smoking cigarettes and expense of meat at baseline and 2 years of follow-up. All current smokers were assumed
to smoke 1 pack per day priced at the average market rate of the most commonly sold brand in 2004 for baseline and in 2007 for follow-up. The actual expenditure
for meat was recorded during the study.
#Additional patient cost and productivity losses. In addition to the patient cost of cigarettes and meat, the productivity loss of the caregiver’s time was also
accounted for.
**Total cost includes consultation, medication, diagnostics, productivity loss, and intervention cost.
††One international US dollar22.65 Pakistan rupees in terms of purchasing power parity. All costs in rupees were multiplied by 22.7.
‡‡Total cost computed with the following multiplication factors: 85 for GP consultation visits (assuming $70 per visit in the United States (http://www.nber.org/
papers/w14568.pdf) and applied to average of $0.73 per visit in the communities in Pakistan; 10 for academic faculty; 15 for medication costs assuming replacement
with generics; 10 for diagnostic tests; 171 for productivity loss (based on average wage $885/wk for 2007 in the United States per US Department of Labor Bureau
of Labor Statistics Quarterly Census of Employment and Wages, Annual Averages 2007); 10 for community health workers’ salaries (assuming minimum hourly wage
$7.75); and 2 for transportation (gas price $2/L in the United States).
Table 7. Sensitivity Analysis: Effect of Decline in Persistence of Effect on CVD DALYs
Benefit in CVD DALYs
Saved Annually, %
Cost per CVD DALYs Averted Annually
Based on Intervention Cost
for Policymaker
Cost per CVD DALYs Annually
Saved Based on Incremental
Cost at Societal Level*
Cost per CVD DALYs Averted Annually
Based on Incremental Cost Derived
From Probabilistic Sensitivity Analysis
at Societal Level*
20 115 1226 1208
16 144 1532 1510
12 192 2043 2014
10 230 2451 2416
CVD indicates cardiovascular disease; DALY, disability-adjusted life-year.
*Based on incremental total healthcare costs between combined home health education plus general practitioner intervention vs usual care.
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interventions (Table 2). However, the combined program was
also the most effective. On the other hand, the HHE only
intervention was costly (annual cost per participant of $3.34) and
less effective compared with no intervention, whereas the trained
GP only intervention had lower costs (annual cost per participant
of $0.65) but lower effects. On the other hand, from a societal
perspective, the incremental costs relative to usual care were
lowest for HHE, although there was no difference in BP levels
compared with usual care (Figure). The trained GP group had
high costs and no difference in benefit. However, the combined
HHE and trained GP intervention had higher costs but also
produced a greater benefit than usual care and thus remained the
most cost-effective intervention.
Current prevention strategies promoted by the World
Health Organization focus on combination drug treatment
(low-dose antihypertensives, statins, and aspirin) to manage
patients’ overall cardiovascular risk profile, which is consid-
ered cost-effective for most low- and middle-income coun-
tries.14 Although such an approach is attractive, the use of
multiple drugs is more expensive, and combined formulations
are not yet available. Moreover, the use of risk charts and the
clinical assessment required are more complicated than tak-
ing a BP measurement. A systematic review of the use of risk
charts did not show any strong evidence of improvements in
care or risk factor outcomes.29
We utilized the existing healthcare infrastructure in Pakistan
to deliver the intervention, hence ensuring logistical feasibility.
The community GPs trained during the study were mostly
private contractors who continued to provide care on their usual
fee-for-service model. Consistent with the pattern of out-of-
pocket coverage for medications in Indo-Asia, antihypertensive
drugs were also primarily bought by the patients. The door-to-
door service of HHE replicated the existing publically funded
Lady Health Workers Program of Pakistan in terms of creden-
tials, frequency of visits, and duty hours of the home educators.
The Lady Health Workers Program of Pakistan has been
implemented for 2 decades and provides immunization and
basic maternal and preventive child care services.30 The syner-
gistic benefit of HHE and GP training on BP lowering in our
study was probably due to mutual reinforcement of healthcare
messages.6 Thus, we show that modest investment in strength-
ening the existing private and public health sectors for BP
control can lead to substantial improvement in patient outcomes
from a societal perspective. Moreover, the demonstration of
success in a largely private physician–dominated healthcare
infrastructure suggests that the observed benefit is likely to be
enhanced further in the long term by reduction in market failure
in the prevention of chronic disease.31
Our results indicate that the majority (60%) of direct
healthcare costs in hypertensive subjects was spent on medica-
tions. The proportional cost of medications became even more
substantial after 2 years in the 2 groups receiving care from
trained GPs (Table 4). The subjects in these groups were also
more likely to be receiving antihypertensive agents, perhaps
reflecting the effectiveness of the update in management guide-
lines that underscored the value of appropriate use of antihyper-
tensive agents (Table 4). These findings are supported by a
nested study in our population linking GP training with better
adherence to antihypertensive medications, which was also
linked with improved BP control.32 Additional efforts to over-
come barriers to thiazide diuretics are likely to further enhance
the economic efficiency of the intervention, as indicated by our
results in which overall costs were reduced by 50% with an
assumption that these agents were used as first-line antihyper-
tensive agents by patients assigned to trained GPs (Table 7).
The combination of low cost and effectiveness in achieving
target BP with the HHE plus trained GP program compares
favorably with the results for a similar program deemed
cost-effective in the US state of Georgia, in which BP control
rates of 68% were achieved with a per capita expenditure of
$7.80.33 Although outcomes data have not been reported, a
train-the-trainers intervention for BP control costing the same
amount has also been implemented successfully across Kyr-
gyzstan, a lower-middle-income country.
The estimated annual per capita combined intervention
cost of $0.43 (or $0.49 inclusive of BP screening) is10% of
the current national budgetary allocation to health ($700
million) in Pakistan and only 14% of the current $2.97 per
capita spending on maternal and child health programs.26
Moreover, even this cost will be offset somewhat when the
program is implemented with the existing Lady Health
Workers Program of Pakistan because considerable resource
sharing is expected. The per capita gross domestic product of
Pakistan is $881 (World Bank estimate for 2007), and the
cost per CVD DALY saved from a societal perspective of the
combined HHE plus trained GP was $1226 per DALY saved.
According to the World Health Organization, an interven-
tion that saves 1 DALY for 3 times the gross domestic
product per capita is considered cost-effective, whereas one
that saves 1 DALY for 1 times the gross domestic product
per capita is considered very cost-effective.34 These recom-
mendations are consistent with $1000 per CVD DALYS
saved being categorized as highly cost-effective for low-
income countries by the Disease Control Priorities Project.35
Moreover, all of the sensitivity analyses indicate that the
estimates associated with the combined intervention fall
within the range qualifying it to be cost-effective. Further-
more, the $115 per DALY saved with the combined
intervention from the policymakers’ perspective is compa-
rable to the existing maternal and neonatal care programs
in South Asia costing $127 to $394 per DALY averted.8
We believe that our findings have significant public health
implications for a substantial proportion of the world’s
population in Indochina, Africa, and countries where the
prevalence of hypertension is high, the mixed public/
private healthcare system is comparable in terms of up-
scaling strategies with the use of a nonphysician workforce
and training of existing healthcare providers to achieve a
similar effect, and a significant share of the healthcare
costs is out of pocket.23,36,37 Thus, the combined strategy of
GP training plus HHE intervention could potentially be an
effective and affordable intervention for many low-income
communities worldwide.28,38
Our analysis has potential limitations. Most studies of
cost-effectiveness use the metric of disability or quality-
adjusted life-years based on deaths and disabilities from
myocardial infarctions and strokes. However, the follow-up
duration in COBRA was short because it was not powered to
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assess differences in these hard outcomes. Instead, the pri-
mary measure of effectiveness was determined by reduction
in BP, an acceptable outcome measure for cost-effectiveness
studies39,40 that is well documented to translate into reduction
in cardiovascular morbidity and mortality.22,41 Second, we did
not take into account any cost incurred during hospitaliza-
tions of subjects in the 4 groups. However, the number of
hospitalizations was too few to make a significant difference
in the results (1% of subjects). Nevertheless, a larger study
for a longer duration is likely to show an even greater benefit
of the combined HHE plus trained GP intervention on
potential relief from the financial burden of catastrophic
illness due to acute cardiovascular events, which often
perpetuates the cycle of poverty in low-income countries.42
Third, our study was conducted in a developing country
setting, and hence generalizability to high-income settings
with greater opportunities for physician education and public
awareness remains unknown.43 Furthermore, the cost differ-
entials, especially those related to healthcare, would be
limited. However, sensitivity analyses that assumed similar
benefit and that replaced costs incurred in Pakistan with those
estimated for the US setting for comparable services in which
international purchasing power parity is used (I$5770 per
CVD DALY averted) as well as after itemized replacements
with rather excessive healthcare costs in the United States
($40 644 per CVD DALY averted) were both within 1 per
capita gross domestic product of the United States (World
Bank estimate $46 627 for 2007) and hence revealed consis-
tent findings. Thus, the combined intervention of HHE by lay
health workers plus trained GPs is likely to be cost-effective
in industrialized countries with high human resource costs as
well. Finally, 22% of subjects were lost to follow-up.
However, they were balanced among the randomized
groups.6 Moreover, we analyzed both costs and effects on an
intention-to-treat principle. The strengths of our study are the
use of empirical cost and effectiveness data and the consis-
tency of results over a range of sensitivity analyses, including
those not accounting for productivity losses, as well as
inclusion of additional cost inputs that further enhanced the
benefit of the combined HHE plus trained GP intervention by
lowering ICER to 17 (95% CI, 5–75; Table 6) and after
assumption of a substantial reduction in effect, although
evidence from a meta-analysis of clinical trials suggests
persistence of effect.44 Furthermore, our study was built on
the existing health system that supports the feasibility, ac-
ceptability, and high likelihood of wide implementation and
sustainability if the intervention is scaled up. Thus, we
believe that our findings are robust and of high validity.
In conclusion, the present analyses show that the combined
intervention of HHE plus trained GP in the management of
hypertension is potentially affordable and significantly more
cost-effective than usual care or either strategy alone in the
communities of Karachi, Pakistan. These results provide
valuable guidance to policymakers for upscaling the com-
bined cost-effective intervention now as well as conducting
further in-depth research on improving CVD outcomes in
Pakistan and other resource-challenged countries with a
rising burden of high BP that demands immediate public
health attention.45
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CLINICAL PERSPECTIVE
High blood pressure (BP) contributes the greatest attributable risk to mortality worldwide. However, evidence on
economically efficient strategies to lower BP from low- and middle-income countries remains scarce. The Control of Blood
Pressure and Risk Attenuation (COBRA) trial randomized 1341 hypertensive subjects in 12 randomly selected
communities in Karachi, Pakistan, to 3 intervention programs compared with usual care: (1) combined home health
education (HHE) by lay health workers plus management by trained general practitioners (GPs); (2) HHE only; and (3)
trained GPs only. The HHE intervention was modeled on the existing Lady Health Workers Program in Pakistan and
provided education on healthy diet, physical activity, and tobacco cessation in the home setting at 3-month intervals. GP
training was an annual 1-day session on optimal hypertension management. Total costs and effects were assessed at
baseline and 2 years to estimate incremental cost-effectiveness ratios based on (1) intervention cost; (2) cost of physician
consultation, medications, diagnostics, changes in lifestyle, and productivity loss; and (3) change in systolic BP. We found
that combined HHE plus GP intervention led to the most BP reduction for the cost (incremental cost-effectiveness ratio of
$23 per mm Hg reduction in systolic BP compared with usual care) and remained so in 97.7% of 1000 bootstrapped
replications. The estimated cost of the combined intervention was $115 per disability-adjusted life-year averted from the
policymakers’ perspective and $1226 per disability-adjusted life-year averted from the societal perspective; $0.43 per
capita population per year would be needed to scale up the intervention in Pakistan. Thus, the combined intervention of
GP training plus HHE intervention could potentially be an effective and affordable strategy for many low- and
middle-income countries worldwide that are urgently in need of efforts to prevent and control hypertension.
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